Newsroom

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

PDF Version Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) […]

read more +
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

PDF Version The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company […]

read more +
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

PDF Version MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, […]

read more +
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

PDF Version MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance […]

read more +
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

PDF Version MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case […]

read more +
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

PDF Version   The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company […]

read more +
Sight Sciences to Report First Quarter Financial Results on May 2, 2024

PDF Version   MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, […]

read more +
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

PDF Version   Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease.   MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing […]

read more +